Medicare beneficiaries’ out-of-pocket costs for insulin exceeded $1 billion in 2020 vs $236 million in 2007.1 High costs lead some patients with diabetes to reduce adherence to insulin, increasing the risk of adverse health outcomes.2-4 [JAMA Network]
Although efforts to cap patients’ cost sharing for insulin have existed in some states since 2020, and in certain Medicare Part D plans since 2021, in January 2023 the Inflation Reduction Act5 capped cost sharing for insulin at $35 for a 1-month supply for all Part D beneficiaries and, therefore, may have a greater effect on adherence. This study measures the association of this cost-sharing cap with insulin fills.
More>
###
